Suppr超能文献

特殊人群的血脂异常管理。

Management of dyslipidemia in special groups.

机构信息

Lakshmi Hospital, Chittur Road, Palakkad, Kerala, India.

Seth G.S. Medical College & KEM Hospital, Mumbai, Maharashtra, India.

出版信息

Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S96-S100. doi: 10.1016/j.ihj.2024.01.018. Epub 2024 Feb 8.

Abstract

Dyslipidemia management in situations like pregnancy, in diseases like rheumatoid arthritis, human immunodeficiency virus (HIV) disease, chronic liver disease, and in the elderly are challenging scenarios. Pregnancy is a contraindication for many drugs. The interaction of various drugs used in HIV infection and rheumatoid arthritis makes it even more difficult to treat with conventional and approved drugs for dyslipidemia. Elderly and chronic renal failure patients often do not tolerate the drugs very well and the data of dyslipidemia management is very different. Lastly, COVID-19 is a unique scenario where clear information is yet to be provided. In this manuscript, the current understanding and available data on the treatment of dyslipidemia in these special situations are discussed.

摘要

在某些情况下,如妊娠、类风湿性关节炎、人类免疫缺陷病毒(HIV)疾病、慢性肝病和老年人等,血脂异常的管理是具有挑战性的。许多药物在妊娠期间都禁用。HIV 感染和类风湿性关节炎中使用的各种药物的相互作用使得用常规和批准的药物治疗血脂异常更加困难。老年和慢性肾衰竭患者通常不能很好地耐受这些药物,血脂异常管理的数据也有很大的不同。最后,COVID-19 是一个独特的情况,目前还没有提供明确的信息。本文讨论了在这些特殊情况下血脂异常治疗的现有认识和可用数据。

相似文献

1
Management of dyslipidemia in special groups.
Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S96-S100. doi: 10.1016/j.ihj.2024.01.018. Epub 2024 Feb 8.
2
Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
Pediatr Nephrol. 2015 Dec;30(12):2073-84. doi: 10.1007/s00467-015-3075-9. Epub 2015 Mar 24.
3
Epidemiology of dyslipidemia in chronic kidney disease.
Clin Exp Nephrol. 2014 Apr;18(2):185-8. doi: 10.1007/s10157-013-0891-8. Epub 2014 Jan 11.
4
Dyslipidemia in Patients with Kidney Disease.
Cardiol Clin. 2021 Aug;39(3):353-363. doi: 10.1016/j.ccl.2021.04.008.
6
Dyslipidemia in patients with chronic kidney disease.
Rev Endocr Metab Disord. 2017 Mar;18(1):29-40. doi: 10.1007/s11154-016-9402-z.
7
Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital.
Vasc Health Risk Manag. 2015 Nov 4;11:563-7. doi: 10.2147/VHRM.S92461. eCollection 2015.

本文引用的文献

1
Blood lipids after COVID-19 infection.
Lancet Diabetes Endocrinol. 2023 Feb;11(2):68-69. doi: 10.1016/S2213-8587(22)00389-8. Epub 2023 Jan 6.
2
Editorial: Dyslipidemia, obesity and coronavirus disease 2019 (COVID-19).
Front Nutr. 2022 Nov 23;9:1019970. doi: 10.3389/fnut.2022.1019970. eCollection 2022.
3
Clinico-epidemiological profile and outcomes of adults with COVID-19: A hospital-based retrospective study in Kerala, India.
J Family Med Prim Care. 2022 Jun;11(6):3000-3005. doi: 10.4103/jfmpc.jfmpc_2273_21. Epub 2022 Jun 30.
4
Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers.
Mayo Clin Proc. 2022 Sep;97(9):1700-1716. doi: 10.1016/j.mayocp.2022.04.005.
5
Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals.
Expert Rev Gastroenterol Hepatol. 2022 Sep;16(9):895-901. doi: 10.1080/17474124.2022.2119128. Epub 2022 Sep 2.
6
High-density lipoproteins may play a crucial role in COVID-19.
Virol J. 2022 Aug 23;19(1):135. doi: 10.1186/s12985-022-01865-4.
7
Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models.
PPAR Res. 2022 Jun 17;2022:5805398. doi: 10.1155/2022/5805398. eCollection 2022.
8
Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis.
J Clin Exp Hepatol. 2022 May-Jun;12(3):818-829. doi: 10.1016/j.jceh.2021.11.010. Epub 2021 Nov 25.
9
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?
Curr Atheroscler Rep. 2022 Jul;24(7):547-556. doi: 10.1007/s11883-022-01030-w. Epub 2022 Apr 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验